Blood-Based Alzheimer’s Tests Are Here, but Not Ready for Widespread Use
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
While new FDA clearances of blood-based early detection tests for Alzheimer’s represent significant progress, limitations remain.
Recent developments suggest that we are on the precipice of a new age offering expanded options for Alzheimer’s diagnosis.
Researchers find that three out of four blood tests produced different results depending on if they were used for White or Black people.
A recent study shows these tests may make it easier and more cost-effective to identify patients for studies of new PET treatments.